๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Myelofibrosis
Clinical trial register · United Kingdom · industry-sponsored

Myelofibrosis Trials in the UK

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 8 Boston 7 Oxford 6 Lincoln 3 Birmingham 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Takeda2 Karyopharm Therapeutics Inc2 Celgene1 Novartis Pharmaceuticals1 iOnctura1
Site city
London8 Boston7 Oxford6 Lincoln3 Birmingham3
All 18 cities
Target enrolment
to
12 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
Takeda
Phase 3
324
Lincoln, Leicester, London, Sunderland, Birmingham
2026-09-02
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naรฏve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Merck Sharp & Dohme LLC
Phase 3
400
London, Boston
2024-05-23
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naรฏve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Karyopharm Therapeutics Inc
Phase 2
58
London
2024-04-22
Recruiting
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
NCT05037760Myelofibrosis
Takeda
Phase 2
135
Boston, Leeds, London
2021-12-16
Active, closed
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156Myelofibrosis
Geron Corporation
Phase 3
327
London, Oxford
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389Myelofibrosis
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
Incyte Corporation
Phase 1
140
Boston, Lincoln, Manchester, Oxford
2021-02-23
Active, closed
A Study to Assess a PI3Kฮด Inhibitor (IOA-244) in Patients With Metastatic Cancers
NCT04328844Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis
iOnctura
Phase 1
210
Glasgow
2020-02-25
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198Myelofibrosis
Sumitomo Pharma America, Inc.
Phase 1/2
240
Lincoln, London, Oxford
2019-12-16
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-uk/condition/myelofibrosis

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.